Region:  
 
      Advanced
Search
 
Bookmark and Share 
  
Find An Educational Offering
Select Search Criteria
Keyword:
Events starting on or after:  mm/dd/yyyy
Events Added:
Region:
Interest Areas (IA): Hold the CTRL key to select or de-select multiple items from adjacent list box

     
Event Type: Hold the CTRL key to select or de-select multiple items from adjacent list box

 
 
  Click here to Expand the Tab 
10305 The 1st DIA Cardiac Safety Workshop in Japan
 Overview 
 Agenda / Committee 
 Continuing Education 
 Tutorial / Sub-Events 
 Exhibits 
 Travel/Hotel Information 
 Registration Fees 
 Related Offerings 
 Highlights 
Title:
The 1st DIA Cardiac Safety Workshop in Japan


Date(s) And Time(s):
May 25 2010 9:00AM - May 26 2010 5:05PM

Location:
Tower Hall Funabori
4-1-1 Funabori
Edogawa-ku
Tokyo
134-0091 Japan

Overview:

Recent, high-profi le, drug-related cardiac adverse eff ects triggered public
and regulatory concerns which resulted in the development of new cardiac
safety regulatory guidance. The ICH-E14 Guidance was fi nalized in May
2005 and was fi rst implemented in the US and Europe. In October 2009
the MHLW offi cially published notifi cation for the implementation of the
ICH-E14 in Japan. While the MHLW E14 version is eff ectively the same as
those released by FDA and EMEA, variations in interpretation are possible.
However, questions such as the predictive value of nonclinical assays,
ethnic diff erences in drug exposure and QT/QTc eff ects, possible need for
extrapolation of foreign QT data, conditions for acceptance of overseas
Thorough QT (TQT) study data for marketing approval in Japan, design
and execution of TQT studies in Japan and the use of positive control in
TQT studies performed in Japan, remain open.

At the same time global experience with TQT study design, performance,
analysis, and interpretation are improving, and sample size is dropping.
In addition, experience with the assessment of cardiovascular safety in
therapeutic areas previously exempted from QT scrutiny, such as oncology
and biological agents, is now developing.

This DIA workshop will provide the fi rst opportunity for an open public
discussion of the implementation of ICH-E14 guidance in Japan. A panel of
academic, industry, and regulatory experts will review and discuss some of
the ongoing and unresolved issues and provide opportunities for interactive
involvement with the audience.

CONFERENCE THEMES
• Implementation of ICH-E14 Cardiac Safety Guidance in Japan
• Strategies for Early Development of Cardiac Safety Database
• Cardiac Safety Biomarkers for Drug-induced Arrhythmia
• Predictive Value of Nonclinical QT/Arrhythmia Assays
• Statistical Methods for Analysis of Thorough QT Data
• Future Trends of Regulatory Review for Cardiac Risk Assessment



Learning Objectives:
CONFERENCE OBJECTIVES
• Stay abreast of emerging trends in cardiac safety risk assessment
• Review evidence for predictive value of nonclinical and clinical QT assays
• Determine emerging paradigms and methods for QT analysis and reporting
• Learn of novel cardiac risk assessment and risk management methods
• Discuss the impact of requirements on drug development strategies
• Novel biomarkers for detection of drug-induced arrhythmia risk


Target Audience:
• Drug development and clinical research managers and associates
• Pharmaceutical physicians and medical directors
• Safety pharmacology and nonclinical scientists
• Drug safety and drug surveillance personnel
• Clinical pharmacology scientists
• Pharmacovigilance managers
• Regulatory aff airs managers
• Biostatisticians
• Data managers
• IT/technology managers
• Outsourcing and marketing managers
• Decision makers in cardiac drug safety, including toxicology, pharmacology and compliance


Event Code:
10305

Contact Information:
For information contact Drug Information Association, LLC
Maruei Building 4F, 2-19-9 Iwamoto-cho, Chiyoda-ku, Tokyo 101-0032 Japan
Tel: 81-3-5833-8444 Fax: 81-3-5820-8448
Email: diajapan@diajapan.org